Key Takeaways
- In the pooled 5-week EMERGENT 1–3 trials, XT separated from placebo on PANSS total and positive subscale scores at the first assessment, while PANSS negative symptom benefits did not reach statistical significance until week 3; this timing can help set expectations for early follow-up.
- Long-term extension data suggest durable benefit with XT: in EMERGENT-4, improvements were sustained through week 52, with 68.6% achieving ≥30% PANSS improvement, 37.1% achieving ≥50% improvement, and 82.9% showing at least a 1-point CGI-S improvement.
- Early gastrointestinal and anticholinergic effects appear front-loaded rather than cumulative; in EMERGENT-4, dry mouth (17.8%), constipation (9.9%), dyspepsia (8.6%), nausea (10.5%), vomiting (6.6%), and diarrhea (5.9%) typically arose within the first 2 weeks, were self-limited, and rarely led to discontinuation.
- Because trospium chloride absorption is reduced by food, XT should be taken without food; the report specifically notes that nausea and vomiting can be problematic if XT is administered after a patient has eaten.
- Medication reconciliation is especially important before starting XT because additive anticholinergic burden may worsen tolerability; the panel specifically advises trimming unnecessary agents such as diphenhydramine and reviewing bladder, COPD, Alzheimer’s disease, and Parkinson’s disease medications.
- The report identifies specific evidence gaps that should temper implementation decisions: recommendations reflect early experience in approximately 200 patients, and there are still no randomized head-to-head comparisons with standard antipsychotics or long-term functional outcome data.
-
Start outpatient XT at 50 mg/20 mg twice daily for 1 to 2 weeks and have patients begin the same evening; most patients stabilize on 100 mg/20 mg–125 mg/30 mg twice daily, but some early-illness patients may do well on 50 mg/20 mg.
-
Prevent early drop-off by prescribing ondansetron 4 mg for 14 days when XT is started, with instructions to re-dose after 30 minutes if symptoms persist.
-
Fasted dosing is a tolerability intervention, not a minor counseling point: XT should be taken on an empty stomach because food reduces trospium chloride absorption and can make nausea and vomiting problematic.
-
When switching to XT, taper the existing antipsychotic by class rather than using a one-size-fits-all schedule: risperidone or paliperidone can often be tapered over several days, while quetiapine, olanzapine, and clozapine usually need 1 to 3 weeks.
-
XT can be used as a dose-sparing add-on in patients already on antipsychotics or LAIs; many patients, possibly as many as 50%, were reported by the panel to be well managed with XT 100 mg/20 mg in combination with a low dose of an atypical antipsychotic.
